Journal Mobile Options
Table of Contents
Vol. 118, No. 2-4, 1999
Issue release date: February–April 1999
Int Arch Allergy Immunol 1999;118:268–270
(DOI:10.1159/000024096)

Promoter Polymorphism in the Candidate Genes, IL–4, IL–9, TGF–β1, for Atopy and Asthma

Rosenwasser L.J.
Division of Allergy and Clinical Immunology, National Jewish Medical and Research Center, Denver, Colo., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

This paper will review genetic variations in the structure of three important candidate genes with varying effects in atopy and asthma that may have significant overall susceptibility associations in relation to the development of atopy and asthma. The three cytokine genes involved are interleukin (IL)–4, IL–9 and transforming growth factor β1, and the nature of the polymorphisms may be related to significantly higher outputs of these cytokines in atopy and asthma.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Borish L, Mascali JJ, Klinnert M, Leppert M, Rosenwasser LJ: SSC polymorphisms in interleukin genes. Hum Mol Genet 1994;3:1710.
  2. Rosenwasser LJ, Klemm DJ, Dresback JK, Inamura H, Mascali JJ, Klinnert M, Borish L: Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995;25(suppl 2):74–78.
  3. Meyers DA, Postma DS, Panhuysen CIM, Xu J, Amelung PJ, Levitt RC, Bleecker ER: Evidence for a locus regulating total serum IgE levels mapping to chromosome 5. Genomics 1994;23:464–470.
  4. Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CI, Meyers DA Levitt RC: Genetic susceptibility to asthma – bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med 1995;333:894–900.
  5. Doull IJM, Lawrence S, Watson M, Begishvili T, Beasley RW, Lampe F, Holgate ST, Morton NE: Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness. Am J Respir Crit Care Med 1996;153:1280–1284.
  6. Hall IP, Wheatley A, Wilding P, Liggett SB: Association of Glu 27 β2–adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995;345:1213–1214.
  7. Turki J, Pak J, Martin RJ, Liggett SB: Genetic polymorphisms of the β2–adrenergic receptor in nocturnal and non–nocturnal asthma. J Clin Invest 1995;95:1635–1641.
  8. Nicolaides NC, Holroyd KJ, Ewart SL, et al: Interleukin 9: A candidate gene for asthma. Proc Natl Acad Sci USA 1997;94:13175– 13180.
  9. Rosenwasser LJ, Borish L: Genetics of atopy and asthma: The rationale behind promoter–based candidate gene studies (IL–4 and IL–10). Am J Respir Crit Care Med 1997;156:S152– S155.

    External Resources

  10. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994; 76:241–251.
  11. Aubert J–D, Dalal BI, Bai TR, Roberts CR, Hayashi S. Hogg JC: Transforming growth factor β1 gene expression in human airways. Thorax 1994;49:225–232.
  12. Toossi Z: Decreased production of TGFβ–1 by human alveolar macrophages as compared with blood monocytes. J Immunol 1996;156: 3461–3468.

    External Resources

  13. Alam R: Transforming growth factor β abrogates the effects of hematopoietins on eosino–phils and induces their apoptosis. J Exp Med 1994;179:1041–1045.
  14. Ohno I, Lea RG, Flanders KC, Clark DA, Banwatt D, Dolovich J, Denburg J, Harley CB, Gauldie J, Jordana M: Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor β1 gene. J Clin Invest 1992;89:1662–1668.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00